• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Adavosertib plus gemcitabine improves survival in platinum-resistant recurrent ovarian cancer

byConstance Wu
February 10, 2021
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Adavosertib plus gemcitabine showed improved progression-free and overall survival in platinum-resistant or refractory recurrent ovarian cancer versus gemcitabine plus placebo.

2. Adavosertib plus gemcitabine was associated with more hematological adverse effects, such as neutropenia, versus control.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Despite advances in the field of oncology, ovarian cancer is amongst the leading causes of death from gynecological malignancies around the world. While platinum-based chemotherapy is generally considered the standard of care, recurrence and subsequent treatment resistance is common. A new approach has been to target molecules involved in the DNA damage response to overcome the resistance to platinum therapy. Both adavosertib and gemcitabine are two such molecules that have shown synergistic effects in preclinical studies of ovarian cancer. This phase 2, double-blind, randomized, controlled trial compared the use of adavosertib plus gemcitabine versus gemcitabine plus placebo in patients with platinum-resistant or refractory recurrent ovarian cancer. Overall, participants in the adavosertib plus gemcitabine group showed improvements in median progression-free and overall survival versus control. The former also showed an improved response according to the cancer antigen-125 (CA-125) criteria. In general, the adavosertib group had more adverse events than the control group; the most common grade 3 or greater adverse events included hematological events and fatigue. Grade 3-4 neutropenias and thrombocytopenias were also more common in the adavosertib group. No treatment-related deaths were recorded. A post-hoc analysis also demonstrated that patients with homologous recombination gene mutations were more likely to respond to the adavosertib plus gemcitabine combination, resulting in a nonsignificant increase in progression-free survival. A notable limitation to this study was the relatively small sample size. Because of this, the researchers were unable to implement stratification factors in their study design. This is an important concern given that, for example, BRCA mutation status is a known prognostic factor not considered in this study.

Click to read the study in The Lancet

Click to read an accompanying editorial in The Lancet

RELATED REPORTS

Minimally invasive surgery is beneficial for epithelial ovarian cancer 

#VisualAbstract: Single-Agent Trabectedin was noninferior to physician’s choice control chemotherapy in recurrent ovarian cancer

#VisualAbstract: Mirvetuximab soravtansine-gynx compared to chemotherapy in folate receptor alpha-positive platinum resistant ovarian cancer led to improved survival

Relevant Reading: Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.

In-Depth [randomized controlled trial]: This double-blind, randomized, placebo-controlled phase 2 trial took place in 11 academic centers in the USA and Canada, and recruited 124 women with platinum-resistant or refractory recurrent ovarian cancer. While 99 participants with high-grade serous ovarian cancer were randomized to the adavosertib plus gemcitabine or the gemcitabine plus placebo group, the other 25 participants with non-high-grade serous ovarian cancer were placed in an exploratory cohort with adavosertib and gemcitabine. The primary endpoint of this study was progression-free survival, with secondary outcomes being response rate, overall survival at 1 year, and safety/tolerability.

Overall, median progression-free survival was improved in the adavosertib group (4.6 months [95% confidence interval [CI] 3.6-6.4] vs. 3.0 months [95% CI 1.8-3.8], hazard ratio = 0.55 [95% CI 0.35-0.90]; p=0.015). Median overall survival was also improved in the adavosertib group (11.4 months [95% CI 8.2-16.5] vs. 7.2 months [95% CI 5.2-13.2], hazard ratio = 0.56 [95% CI=0.35-0.91]; p=0.017). A nonsignificant improved response by CA-125 criteria was seen in the adavosertib group (23% vs. 9%, p=0.16). The participants in the gemcitabine plus adavosertib group had more grade 3 or higher adverse events than gemcitabine with placebo. Examples include grade 3-4 neutropenia (62% with adavosertib vs. 30% with control) and thrombocytopenia (31% with adavosertib vs. 6% with control). In a post-hoc analysis, patients with homologous recombination gene mutations, such as CCNE1, had an improved response to adavosertib (Fisher’s exact test p =0.013). This was also associated with a nonsignificant increase in progression-free survival (log-rank p=0.13).

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adavosertibgemcitabineovarianovarian cancer
Previous Post

Naltrexone-bupropion treatment provides a higher response for methamphetamine use disorder

Next Post

Pregnancy outcomes in women with moderate-to-severe psoriasis

RelatedReports

All Specialties

Minimally invasive surgery is beneficial for epithelial ovarian cancer 

July 4, 2025
#VisualAbstract: Single-Agent Trabectedin was noninferior to physician’s choice control chemotherapy in recurrent ovarian cancer
StudyGraphics

#VisualAbstract: Single-Agent Trabectedin was noninferior to physician’s choice control chemotherapy in recurrent ovarian cancer

May 24, 2024
#VisualAbstract: Mirvetuximab soravtansine-gynx compared to chemotherapy in folate receptor alpha-positive platinum resistant ovarian cancer led to improved survival
StudyGraphics

#VisualAbstract: Mirvetuximab soravtansine-gynx compared to chemotherapy in folate receptor alpha-positive platinum resistant ovarian cancer led to improved survival

December 28, 2023
Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
Infectious Disease

Specific viruses may be associated with increased risk and worse outcomes of ovarian cancer

December 8, 2023
Next Post
Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

Pregnancy outcomes in women with moderate-to-severe psoriasis

#VisualAbstract: Endocrine therapy plus oral S-1 improves invasive  disease-free survival in patients with ER⁺ breast cancer

#VisualAbstract: Endocrine therapy plus oral S-1 improves invasive disease-free survival in patients with ER⁺ breast cancer

Risk factors for SARS-CoV-2 seropositivity in health care workers

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
  • Nerandomilast slows FVC decline in progressive pulmonary fibrosis
  • 2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.